CD19 and plasma cell myeloma: In another study of multiple myeloma, Kang et al. confirmed the increased anti-tumor reactivity of TanCAR-T cells against cells expressing CD19 and BCMA relative to CD19- or BCMA-specific CAR-T cells alone [82].